Sumokla, Baby Boy -.

HRN: 22-18-79  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/18/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/18/2022
11/25/2022
IV
38mg
Q24
Sepsis Neonatorum
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: